Podiatry, Foot & Ankle Surgery and Advanced Wound Care Platform MSO
Integrate clinical podiatry offices with mobile skilled nursing wound care programs, manage high-cost cellular tissue product (CTP) skin graft Buy-and-Bill inventory, and command 11x–14x EBITDA valuations.
Podiatric medicine and advanced wound care represent highly resilient outpatient healthcare sectors fueled by rising rates of diabetes, peripheral artery disease (PAD), and population aging. Standalone podiatry practices often trade at modest valuations (4x–6x EBITDA) due to small clinic footprints. However, consolidating podiatry groups with advanced wound healing centers—incorporating Cellular and Tissue-Based Products (CTPs/skin substitutes), hyperbaric oxygen therapy (HBOT), and institutional Skilled Nursing Facility (SNF) rounds—generates immense normalized EBITDA. Concurrently, aggressive Medicare MAC audits on amniotic allograft J-codes (Q4100 series) demand rigorous compliance. Kompanie LLP guides PE sponsors in architecting defensible, high-multiple podiatry platforms.
Deliverables
- Turnkey Friendly DPM Professional Corporation charters.
- Cellular Tissue Product (CTP) Procurement & Compliance Manual.
- Compliant Skilled Nursing Facility Service Agreement templates.
- Podiatric surgeon wRVU production formula and rollover equity models.
Execution phases
- Stage 1: Allograft & Wound Care Forensics — Audit 100% of skin substitute claims against regional Medicare LCD policies (Novitas, Noridian), verify invoice acquisition costs, and inspect SNF contracts.
- Stage 2: Centralized Wound Care Supply & MSO Charters — Draft Friendly Podiatry DPM PC charters, centralize specialty allograft procurement to capture 20%+ volume discounts, and establish uniform charting.
- Stage 3: Mobile Wound Care Expansion & ASC Integration — Deploy mobile wound care vans servicing regional assisted living and nursing home facilities, funneling reconstructive surgeries into platform ASCs.
Diligence red flags
- Podiatry platform billing amniotic tissue allografts (Q-codes) without documented 4-week trials of standard conservative wound therapy, triggering 100% Medicare recoupment.
- Significant skin substitute product wastage (Modifier JW) billed without documented discarded square-centimeter milligram remnants.
- SNF nursing home contracts providing free clinical services in exchange for exclusive surgical patient referrals, violating Anti-Kickback statutes.
- Clearinghouses stripping routine foot care CPT 11719/11721 claims due to missing class finding modifiers (Q7, Q8, Q9).
Frequently asked questions
Why are cellular tissue products (skin substitutes) heavily audited by Medicare in podiatry?
Skin substitutes carry high reimbursement rates ($800 to $2,500 per application). Medicare MACs rigorously audit claims to ensure the patient had a chronic diabetic ulcer or venous stasis ulcer that failed conservative therapy for at least 30 days.
How does mobile wound care expand podiatry platform EBITDA?
Contracting directly with regional nursing homes and assisted living facilities allows a single wound care podiatrist to treat 25 to 40 complex patients per day on-site, generating predictable institutional recurring cash flow.